Semaglutide Guidelines for Glycemic Control

Dosing and Administration

The American College of Cardiology recommends initiating semaglutide at 0.25 mg subcutaneously once weekly for 4 weeks, then increasing to 0.5 mg once weekly, with further titration to 1 mg or 2 mg as needed for optimal glycemic control 1
Oral semaglutide should be started with 3 mg once daily for 1 month, increased to 7 mg once daily for at least 1 month, and then to a maximum dose of 14 mg once daily if additional glycemic control is needed 2
Oral semaglutide requires strict administration protocol, taken on an empty stomach with no more than 4 ounces of plain water, at least 30 minutes before the first food, beverage, or other oral medications of the day 2

Gastrointestinal effects are the most common adverse events with both injectable and oral semaglutide, including nausea, diarrhea, vomiting, abdominal pain, and constipation 2, 3
The gradual dose titration schedule is designed to minimize gastrointestinal side effects 1, 2
There is a potential risk of diabetic retinopathy complications 4 and a rare risk of diabetic ketoacidosis 3
No dosage adjustment is required for patients with renal impairment, but use with caution in patients with severe hepatic impairment due to limited clinical experience 1, 2
Contraindicated in patients with personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) 2, 4

Semaglutide has demonstrated significant reductions in HbA1c and weight reduction in clinical trials, although specific data is not available 1, 2
Gradual dose titration is essential to minimize gastrointestinal adverse effects 1, 2
Monitor for hypoglycemia when used with insulin or insulin secretagogues 2

Semaglutide was approved by the FDA for treatment of type 2 diabetes, with the SUSTAIN-6 trial serving as the initial regulatory approval study 5, 6

This cardiovascular indication is based on the SUSTAIN-6 trial, which demonstrated that semaglutide reduced the primary composite outcome (cardiovascular death, nonfatal MI, or nonfatal stroke) from 8.9% in the placebo group to 6.6% in the semaglutide group (HR 0.74; 95% CI 0.58-0.95) 5, 6
The cardiovascular benefit was demonstrated in patients with type 2 diabetes at high cardiovascular risk or with established cardiovascular disease 7, 8

Ozempic is contraindicated in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) based on animal studies showing thyroid C-cell tumors 9

The weight loss observed with Ozempic in diabetes trials (mean weight loss ranging from 4-6 kg in cardiovascular outcome trials) is considered a beneficial side effect rather than a primary indication 5, 6
While subcutaneous semaglutide at 2.4 mg (marketed as Wegovy) was FDA-approved for chronic weight management in obesity in 2021, Ozempic itself is not FDA-approved for obesity treatment 10, 11